TCRX,TScan Therapeutics, Inc. | Healthcare

Healthcare

TCRX

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

TScan Therapeutics, Inc.TCRX

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.

It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors.

The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors.

In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease.

TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Latest News >

Cannae, KDSA to Buy Majority Stake in The Watkins Company

Oct 7, 2024

04:59 PM EDT, 10/07/2024 (MT Newswires) -- Cannae Holdings ( CNNE ) and KDSA Investment Partners said Monday they have agreed to buy a majority stake in The Watkins Company, a flavoring products company. The current majority owner and Chairman, Mark Jacobs, will roll a significant equity stake into the transaction, the companies said. They expect to close the deal...

PRECIOUS-Gold flat as markets await Fed minutes

Oct 7, 2024

Oct 8 (Reuters) - Gold prices were flat in early Asian hours on Tuesday as market participants awaited minutes of the U.S. Federal Reserve's last meeting and more economic data for further clarity on policy easing this year. FUNDAMENTALS * Spot gold was little changed at $2,643.68 per ounce, as of 0013 GMT. U.S. gold futures fell 0.1% to $2,662.90....

Samsung's Q3 profit misses estimates as it struggles in AI chips

Oct 7, 2024

SEOUL, Oct 8 (Reuters) - Samsung Electronics ( SSNLF ) estimated on Tuesday its third-quarter operating profit jumped 274%, but that was short of analysts' estimates as the tech giant struggled to capitalise on strong demand for chips used in artificial intelligence servers. The world's largest memory chip, smartphone and TV maker estimated an operating profit of 9.1 trillion won...

Japan's Nikkei falls after Wall Street's weak finish

Oct 7, 2024

TOKYO, Oct 8 (Reuters) - Japan's Nikkei share average retreated on Tuesday, weighed down by Wall Street's weak finish overnight and rising U.S. yields on reduced bets of another large rate cut following Friday's strong jobs report. The Nikkei was down 0.8% at 39,016.79, as of 0008 GMT, after closing 1.8% higher on Monday. The broader Topix was down 0.98%...